Tagged with Exclusive

Global Gilead Sciences’ Jacopo Andreose PhD is a 20+ year pharma veteran and is today responsible for setting company strategy, planning and execution for over 150 countries across Asia, Russia/CIS, Latin and Central America, the Middle East, and Africa. In an exclusive conversation, Andreose outlines how Gilead was able to roll…

Switzerland In an exclusive interview, Jean-Paul Clozel explains Idorsia’s unique value proposition as a biotech focused on small molecules, how agnosticism in terms of therapeutic areas leads to more innovative medical breakthroughs, and why scientific innovation continues to motivate him.   When you have started two companies, people think that you…

Asia-Pacific In an exclusive and wide-ranging interview, Takeda APAC SVP Thomas Willemsen outlines his strategy for bringing the company’s specialty pharma portfolio to the diverse group of countries that make up the APAC region, the potential significance of Takeda’s upcoming dengue vaccine, and what Asia’s contribution to global healthcare and life…

Coronavirus The CEOs and top executives, David Ricks, chairman and CEO, Eli Lilly & Co and IFPMA president, Severin Schwan, CEO, Roche, Paul Stoffels, chief scientific officer, Johnson & Johnson, David Loew, executive VP, Sanofi Pasteur and Rajeev Venkayya, president, Global Vaccines Business Unit, Takeda took part in a virtual press…

Global Greg Reh leads Deloitte’s global life sciences sector which includes clients in biopharma, medtech, generics and distribution businesses, as well as non-profit patient advocacy organizations and regulatory agencies. He discusses talent acquisition and retention in global life sciences today, the challenges around data and AI uptake, and the future of…

Global In an exclusive and wide-ranging interview, Tom O’Leary, chief information officer (CIO) of leading contract research organisation (CRO), ICON, highlights how data is already revolutionising the CRO industry and the steps that still need to be taken to better match patients with targeted therapies and improve health outcomes. O’Leary also…

France Olivier Laureau, global president of Servier Group, outlines the impact of recent acquisitions, the significance of Servier’s recently-opened commercial subsidiary in the US, the ongoing importance of France to the global group, and Servier’s unique value proposition as a privately-owned R&D-focused company.   The acquisition of Shire products also allowed…

USA Speaking exclusively to PharmaBoardroom at the 2017 BIO Convention in San Diego, former FDA Commissioner Andrew von Eschenbach lifts the lid on the ‘FDA Beyond Our Borders’ project that he initiated. Dr. von Eschenbach, you were the FDA Commissioner for three years, from 2006 to 2009. What do you see…

Luxembourg In an exclusive interview, Romain Schneider, Minister of Social Security for Luxembourg, on the successes of the Luxembourgish social security system, areas for improvement, and Luxembourg’s positioning within Europe. You were appointed Minister of Social Security nearly three years ago now, in December 2013. What have been the main changes…

Luxembourg In an exclusive interview, Luxembourg’s dedicated Minister for Health provides a passionate insight into how the country is developing an improved and integrated healthcare system with patients at the very centre of their efforts.   We could play a bigger role in the industry by becoming an innovative hub for…

Health Gabriel O’Shea, National Commissioner of Seguro Popular, on how the institute generates more efficient and transparent resource allocation across Mexico as the country prepares to implement medical service exchange among the various social security institutes. Beside this step towards universal health care in Mexico, he also reveals how Seguro Popular…

Pharma The general manager of ALK Czech Republic and Slovakia on his strategy which led to success within the first one and a half years of ALK’s physical presence in the cluster. Furthermore, he highlights the significance of having the right people in the right place and positioning the company as…